Drug Profile
CB 189625
Alternative Names: CB-189,625; CB-625Latest Information Update: 03 May 2016
Price :
$50
*
At a glance
- Originator Cubist Pharmaceuticals; Hydra Biosciences
- Class Analgesics; Small molecules
- Mechanism of Action TRPA1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
- 31 Dec 2012 Phase-I clinical trials in healthy volunteers in USA (unspecified route)
- 17 Mar 2011 Preclinical development is ongoing in USA